Earnings call transcript: Polestar misses Q2 2026 EPS as shares fall premarket

Polestar reported adjusted EPS of -$2.19 vs -$1.81 expected (a $0.38 or 20.99% miss) as Q2 revenue fell 8% to $727M amid pricing pressure, tariffs, and a U.S. Commerce Department setback. The stock dropped 9.92% premarket to $10.8, with cash down to $888M (from $1.159B at year-end 2025) and leverage/liquidity risks highlighted by a 0.43 current ratio and -$1.07B levered free cash flow over the last 12 months. Management lowered full-year volume guidance to low- to mid-single-digit growth and said it will not appeal the decision blocking U.S. sales of model year 2027+ vehicles, while targeting reduced cash burn in H2 via lower CapEx and working-capital improvements.

Analysis

Polestar’s print is less about one bad quarter and more about the market repricing the equity from a growth story into a financing-and-survival story. The U.S. regulatory loss removes a meaningful terminal option, so even if Europe/Asia volumes hold, the business now has to absorb a structurally smaller addressable market with the same fixed overhead; that is usually what keeps auto equities cheap for years. The immediate winner is not another EV pure-play but established premium OEMs with better scale economics and less need to subsidize demand.

The balance sheet is the real catalyst chain over the next 1-3 months. Management has bought time, but liquidity is now a function of execution on H2 cash burn: if working capital release and the SUV ramp do not materially narrow the burn rate, the market will start pricing the next dilution event before year-end. That makes any rally vulnerable unless the company can show gross margin improvement plus cash conversion, not just unit growth.

Contrarianly, the consensus may be overstating near-term bankruptcy risk while understating long-dated dilution risk. Sponsor support from Volvo/Geely likely keeps the lights on, which caps default odds, but that same support can keep the equity permanently subordinated and cheaply financed. On the NVDA side, the reported AI-platform acquisition is strategically more important than financially accretive in the next quarter: if true, it tightens ecosystem lock-in and supports multiple expansion more than it changes FY26 numbers.

Key Decisions for Investors

• PSNY: fade any post-earnings bounce into $12-$13 over the next 1-3 weeks; use a short equity or small put spread to target a move back toward single digits. Stop if H2 cash-burn commentary improves materially or if the stock reclaims $13.50 on volume.
• PSNY: for better convexity, buy 1-3 month $10/$7.5 put spreads only if management fails to show visible Q3 delivery and cash-flow traction; this limits premium burn versus outright shorting a high-beta name with sponsor support.
• PSNY: watchlist alert, not a fresh short, if Q3 operating cash outflow stays above roughly $150M/quarter or if management hints at another capital raise. Those would be the cleanest falsifiers for the bear case and the trigger for a larger downside leg.
• NVDA: if the reported Hugging Face deal is confirmed, buy dips rather than chase the open; the trade is multiple support and ecosystem control, so a 1-2 month horizon favors long exposure on weakness over an immediate event-driven sprint.
• Pair trade idea: long NVDA / short PSNY on a market-neutral basis. The thesis is that NVDA’s strategic optionality deserves multiple expansion, while PSNY’s U.S. exit and financing overhang should keep equity value capped despite operational progress.